[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581897":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":39,"collaborators":11,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":11,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Zhejiang Provincial People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.","EXPERIMENTAL",null,[13],"Drug: NKG2D CAR-NK with PD-1 Antibody",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","NKG2D CAR-NK with PD-1 Antibody","Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Minghua Ge","CONTACT","+86-0571 87666666","geminghua@hmc.edu.cn",[27],{"facility":5,"status":11,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":11},"Hangzhou","Zhejiang","310014","China","CN",{"type":34,"coordinates":35},"Point",[36,37],120.16142,30.29365,{"lat":37,"lon":36},{"type":40,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100581897","phase-1-clinical-study-of-nkg2d-car-nk-combined-with-pd-1-monoclonal-antibody-in-the-treatment-of-atc-100581897",false,"NCT06856278","Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC","Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)","Inclusion Criteria:\n\n1. Age 18-75 years (including boundary values), male or female.\n2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.\n3. Liver and kidney function is good, and can tolerate treatment.\n4. Be able to cooperate with the completion of treatment and follow-up work.\n5. No other systemic diseases, including other malignancies.\n\nExclusion Criteria:\n\n1. Need to breastfeed the baby or have fertility needs；\n2. Immune system diseases;\n3. Diseases of the blood system;\n4. Mental system diseases;\n5. Interstitial pneumonia, lung disease, etc.;\n6. Failure to follow rules of this study.","ALL","18 Years","75 Years",{"count":52,"type":53},30,"ESTIMATED","INTERVENTIONAL",[56,57],"PHASE1","PHASE2","The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.",[60],"Anaplastic Throid Carcinoma","NOT_YET_RECRUITING","2025-02-26",{"date":64,"type":65},"2025-03-04","ACTUAL",{"date":67,"type":53},"2025-02-22",{"date":69,"type":53},"2029-03-01",{"name":5,"class":6},1]